Quick Answer
Revolution Medicines, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Revolution Medicines, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 -100.0% |
$11.58M -67.3% |
$35.38M +20.4% |
$29.39M -31.6% |
$42.98M -14.1% |
| Revenue (ASC 606) | $0.00 | $0.00 -100.0% |
$11.58M -67.3% |
$35.38M +20.4% |
$29.39M -31.6% |
$42.98M -14.1% |
| Net Income | -$1.13B -88.5% |
-$600.09M -37.5% |
-$436.37M -75.5% |
-$248.71M -32.9% |
-$187.09M -73.0% |
-$108.16M -126.9% |
| Diluted EPS | -$5.95 -66.2% |
-$3.58 +7.3% |
-$3.86 -25.3% |
-$3.08 -19.8% |
-$2.57 -27.9% |
-$2.01 |
| Total Assets | $2.35B -8.0% |
$2.56B +24.1% |
$2.06B +153.9% |
$811.93M +10.0% |
$737.99M +30.1% |
$567.40M +157.3% |
| Cash and Equivalents | $383.75M -29.3% |
$543.06M -22.0% |
$696.15M +331.3% |
$161.41M +48.8% |
$108.50M +4.1% |
$104.27M +525.9% |
| Stockholders Equity | $1.63B -28.0% |
$2.27B +24.0% |
$1.83B +166.5% |
$685.19M +13.7% |
$602.57M +26.9% |
$474.68M +411.1% |
| R&D Expense | $987.33M +66.7% |
$592.23M +40.0% |
$423.14M +67.2% |
$253.07M +35.4% |
$186.95M +41.4% |
$132.25M +44.1% |
| Operating Income | -$1.18B -71.5% |
-$689.52M -41.5% |
-$487.19M -88.6% |
-$258.28M -37.4% |
-$188.01M -69.8% |
-$110.70M -104.5% |
| Shares Outstanding | 197.00M +6.0% |
185.90M +12.9% |
164.67M +82.1% |
90.41M +21.9% |
74.14M +11.3% |
66.60M +1923.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2024 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2024 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$305.21M | -95.3% | -23.2% |
| Diluted EPS | September 30, 2025 | -$1.61 | -71.3% | -22.9% |
| Total Assets | September 30, 2025 | $2.25B | +27.7% | -7.3% |
| Cash and Equivalents | September 30, 2025 | $217.44M | +8.0% | -46.0% |
| Stockholders Equity | September 30, 2025 | $1.60B | +2.0% | -14.4% |
| R&D Expense | September 30, 2025 | $262.51M | +73.0% | +17.1% |
| Operating Income | September 30, 2025 | -$315.27M | -79.4% | -19.1% |
| Shares Outstanding | September 30, 2025 | 189.71M | +13.1% | +1.5% |
- Revolution Medicines, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Revolution Medicines, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Revolution Medicines, Inc. reported Net Income of -$1.13 billion for fiscal year 2025.
- Revolution Medicines, Inc. showed a decrease of -88.5% in Net Income compared to the prior fiscal year.
- Revolution Medicines, Inc. reported Diluted EPS of $5.95 per share (loss) for fiscal year 2025.
- Revolution Medicines, Inc. showed a decrease of -66.2% in Diluted EPS compared to the prior fiscal year.
- Revolution Medicines, Inc. reported Total Assets of $2.35 billion for fiscal year 2025.
- Revolution Medicines, Inc. showed a decrease of -8.0% in Total Assets compared to the prior fiscal year.
- Revolution Medicines, Inc. reported Cash and Equivalents of $383.75 million for fiscal year 2025.
- Revolution Medicines, Inc. showed a decrease of -29.3% in Cash and Equivalents compared to the prior fiscal year.
- Revolution Medicines, Inc. reported Stockholders Equity of $1.63 billion for fiscal year 2025.
- Revolution Medicines, Inc. showed a decrease of -28.0% in Stockholders Equity compared to the prior fiscal year.
- Revolution Medicines, Inc. reported R&D Expense of $987.33 million for fiscal year 2025.
- Revolution Medicines, Inc. showed an increase of +66.7% in R&D Expense compared to the prior fiscal year.
- Revolution Medicines, Inc. reported Operating Income of -$1.18 billion for fiscal year 2025.
- Revolution Medicines, Inc. showed a decrease of -71.5% in Operating Income compared to the prior fiscal year.
- Revolution Medicines, Inc. reported Shares Outstanding of 197.00 million shares for fiscal year 2025.
- Revolution Medicines, Inc. showed an increase of +6.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: